A large network meta-analysis of 75 trials, which included 95,444 participants, demonstrated that combinations of conventional HF drugs (ACEis/ARBs, BBs, and MRAs) and newer drugs (ARNis, SGLT2is, HCN blockers, sGC stimulators, and selective cardiac myosin activators) were effective in reducing the all-cause mortality, cardiovascular death, and HF rehospitalization [10]. The gene discussed is SGCB; the disease is hydrops fetalis.